Attenuation of tumor cell‐mediated immunosuppression can occur through release of soluble factors (e.g., TGFβ, IL‐6, IL‐10, VEGF, etc.)which directly or indirectly affect T‐cell immunity (e.g., through augmented induction of myeloid suppressive cells, MDSCs which block production of mature DCs), and/or through tumor‐cell‐mediated enhancement of immunoregulatory pathways 7, 20. The gene discussed is VEGFA; the disease is neoplasm.